APA (7th ed.) Citation

Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., . . . Neoptolemos, J. P. (2023). Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): A four-arm, multicentre, randomised, phase 2 trial. The lancet. Gastroenterology & Hepatology, 8(2), . https://doi.org/10.1016/S2468-1253(22)00348-X

Chicago Style (17th ed.) Citation

Ghaneh, Paula, et al. "Immediate Surgery Compared with Short-course Neoadjuvant Gemcitabine Plus Capecitabine, FOLFIRINOX, or Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Cancer (ESPAC5): A Four-arm, Multicentre, Randomised, Phase 2 Trial." The Lancet. Gastroenterology & Hepatology 8, no. 2 (2023). https://doi.org/10.1016/S2468-1253(22)00348-X.

MLA (9th ed.) Citation

Ghaneh, Paula, et al. "Immediate Surgery Compared with Short-course Neoadjuvant Gemcitabine Plus Capecitabine, FOLFIRINOX, or Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Cancer (ESPAC5): A Four-arm, Multicentre, Randomised, Phase 2 Trial." The Lancet. Gastroenterology & Hepatology, vol. 8, no. 2, 2023, https://doi.org/10.1016/S2468-1253(22)00348-X.